Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.34 - $9.01
Previous CloseN/A
Volume359.32K
Average Volume (3M)4.03M
Market Cap
$225.64M
Enterprise Value$1.19B
Total Cash (Recent Filing)$173.17M
Total Debt (Recent Filing)$413.92M
Price to Earnings (P/E)130.6
Beta0.86
Next Earnings
May 01, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding160,028,380
10 Day Avg. Volume3,468,075
30 Day Avg. Volume4,033,823
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.60
Price to Cash Flow (P/CF)5.70
P/FCF Ratio5.70
Enterprise Value/Market Cap5.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.51
Enterprise Value/Ebitda11.18
Forecast
1Y Price Target
$8.00Price Target Upside436.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Ironwood Pharma News
PremiumCompany Announcements
Ironwood Pharma Delays 10-K Filing Due to Internal Issues
PremiumCompany Announcements
Ironwood Pharmaceuticals Reports 2024 Financial Results
PremiumCompany Announcements
Ironwood Pharmaceuticals’ Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Financial StrategyManagement continues to focus on strengthening the balance sheet by paying down debt and expects further reduction in debt through LINZESS cash flows.
Product GrowthThe apraglutide opportunity could help drive growth over the longer term.
RestructuringThe company announced a restructuring to help counterbalance decaying Linzess revenues.
Bears Say
Price ErosionLinzess faces price erosion from the Medicare Part D redesign, affecting the 2025 outlook.
Revenue DeclineThere is uncertainty over the company's balance sheet due to eroding Linzess revenues.
Stock PerformanceThe restructuring better positions the company for its future, but coupled with a very cautious 2025 guide for Linzess and a ~6-month delay to completion of the apraglutide NDA filing, we do not see a clear path to near-term stock performance and believe the difficult calculus on the balance sheet will weigh on shares for the foreseeable future.
---
Ownership Overview
13.19% Insiders
17.11% Mutual Funds
33.53% Other Institutional Investors
12.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $1.34 and its highest was $9.01 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $225.64M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Feb 27, 2025. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.085 by -$0.065.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.285 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is -0.03.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 160,028,380 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of $0.02 in its last earnings report, missing expectations of $0.085. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in IRWD
---
Ironwood Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (436.91% Upside)
$8.00 (436.91% Upside)
Blogger Sentiment
Bearish
IRWD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 52.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.38%
12-Months-Change
Fundamentals
Return on Equity
-8.02%
Trailing 12-Months
Asset Growth
-25.43%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
---
IRWD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong demand growth for LINZESS and promising data for apraglutide, suggesting potential future growth. However, concerns about pricing headwinds from Medicare Part D redesign and cash liquidity tempered the overall outlook.Read More>---
IRWD Stock 12 Month Forecast
Average Price Target
$8.00
▲(436.91% Upside)
Technical Analysis
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-59.25%
reiterated a buy rating 27 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.25% per trade.
---